References

1. Yuguang Huang,Xiaohan Xu (2016). Faculty Opinions recommendation of Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..
2. E Benjamin,P Muntner,A Alonso,M Bittencourt,C Callaway,A Carson (2019). American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.
3. Dominick Raphael,Laurine Roos,Victor Myovela,Elisante Mchomvu,Jabir Namamba,Said Kilindimo,Winfrid Gingo,Christoph Hatz,Daniel Paris,Maja Weisser,Richard Kobza,Martin Rohacek (2018). Heart diseases and echocardiography in rural Tanzania: Occurrence, characteristics, and etiologies of underappreciated cardiac pathologies.
4. S Okutucu,N Bursa (2019). Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis.
5. P Piotr,A Adriaan,D Stefan (2016). The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
6. Naoki Okumura,Pardeep Jhund,Jianjian Gong,Martin Lefkowitz,Adel Rizkala,Jean Rouleau,Victor Shi,Karl Swedberg,Michael Zile,Scott Solomon,Milton Packer,John Mcmurray (2016). Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
7. V Maria,S Angelo,Antonella Gennaro,V,Federica,Elena (2020). Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.
8. John Mcmurray,David Demets,Silvio Inzucchi,Lars Køber,Mikhail Kosiborod,Anna Langkilde,Felipe Martinez,Olof Bengtsson,Piotr Ponikowski,Marc Sabatine,Mikaela Sjöstrand,Scott Solomon (2019). A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF).
9. Writing Committee,T Maddox,J Januzzi,Jr,L Allen,K Breathett,J Butler (2021). Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
10. Faiez Zannad,João Ferreira,Stuart Pocock,Stefan Anker,Javed Butler,Gerasimos Filippatos,Martina Brueckmann,Anne Ofstad,Egon Pfarr,Waheed Jamal,Milton Packer (2020). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
11. S Gubelli,M Caivano (2019). Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan.
12. Dominick Raphael,Zhiyu Liu,Zhi Jin,Xinyue Cui,Dongjian Han,Weiwei He,Jiahong Shangguan,Deliang Shen (2021). Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
13. Andrew House,Christoph Wanner,Mark Sarnak,Ileana Piña,Christopher Mcintyre,Paul Komenda,Bertram Kasiske,Anita Deswal,Christopher Defilippi,John Cleland,Stefan Anker,Charles Herzog,Michael Cheung,David Wheeler,Wolfgang Winkelmayer,Peter Mccullough,Ali Abu-Alfa,Kerstin Amann,Kazutaka Aonuma,Lawrence Appel,Colin Baigent,George Bakris,Debasish Banerjee,John Boletis,Biykem Bozkurt,Javed Butler,Christopher Chan,Maria Costanzo,Ruth Dubin,Gerasimos Filippatos,Betty Gikonyo,Dan Gikonyo,Roger Hajjar,Kunitoshi Iseki,Hideki Ishii,Greg Knoll,Colin Lenihan,Krista Lentine,Edgar Lerma,Etienne Macedo,Patrick Mark,Eisei Noiri,Alberto Palazzuoli,Roberto Pecoits-Filho,Bertram Pitt,Claudio Rigatto,Patrick Rossignol,Soko Setoguchi,Manish Sood,Stefan Störk,Rita Suri,Karolina Szummer,Sydney Tang,Navdeep Tangri,Aliza Thompson,Krishnaswami Vijayaraghavan,Michael Walsh,Angela Yee-Moon Wang,Matthew Weir (2019). Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
14. Wilfried Mullens,Pieter Martens (2019). Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation.
15. Duk-Hyun Kang,Sung-Ji Park,Sung-Hee Shin,Geu-Ru Hong,Sahmin Lee,Min-Seok Kim,Sung-Cheol Yun,Jong-Min Song,Seung-Woo Park,Jae-Joong Kim (2019). Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
16. Bassam Atallah,Ziad Sadik,Mohamed Hisham,Oussama Kalagieh,Iman Hamour,Guirgis Gabra,Mosaad El Banna,Medhat Soliman,Antoine Cherfan,Feras Bader (2019). A Per-Protocol Initiation of Sacubitril/Valsartan in an Advanced Heart Failure Disease Management Programme in the Middle East Gulf Region.
17. M Mapelli,C Vignati,S Paolillo,De Martino,F Righini,F Agostoni,P (2019). Sacubitril/valsartan can improve exercise performance in systolic chronic heart failure patients: a case report.
18. Stefan Anker,Javed Butler,Gerasimos Filippatos,João Ferreira,Edimar Bocchi,Michael Böhm,Hans-Peter Brunner–la Rocca,Dong-Ju Choi,Vijay Chopra,Eduardo Chuquiure-Valenzuela,Nadia Giannetti,Juan Gomez-Mesa,Stefan Janssens,James Januzzi,Jose Gonzalez-Juanatey,Bela Merkely,Stephen Nicholls,Sergio Perrone,Ileana Piña,Piotr Ponikowski,Michele Senni,David Sim,Jindrich Spinar,Iain Squire,Stefano Taddei,Hiroyuki Tsutsui,Subodh Verma,Dragos Vinereanu,Jian Zhang,Peter Carson,Carolyn Lam,Nikolaus Marx,Cordula Zeller,Naveed Sattar,Waheed Jamal,Sven Schnaidt,Janet Schnee,Martina Brueckmann,Stuart Pocock,Faiez Zannad,Milton Packer (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
19. Scott Solomon,John Mcmurray,Brian Claggett,Rudolf De Boer,David Demets,Adrian Hernandez,Silvio Inzucchi,Mikhail Kosiborod,Carolyn Lam,Felipe Martinez,Sanjiv Shah,Akshay Desai,Pardeep Jhund,Jan Belohlavek,Chern-En Chiang,C Borleffs,Josep Comin-Colet,Dan Dobreanu,Jaroslaw Drozdz,James Fang,Marco Alcocer-Gamba,Waleed Al Habeeb,Yaling Han,Jose Cabrera Honorio,Stefan Janssens,Tzvetana Katova,Masafumi Kitakaze,Béla Merkely,Eileen O’meara,Jose Saraiva,Sergey Tereshchenko,Jorge Thierer,Muthiah Vaduganathan,Orly Vardeny,Subodh Verma,Vinh Pham,Ulrica Wilderäng,Natalia Zaozerska,Erasmus Bachus,Daniel Lindholm,Magnus Petersson,Anna Langkilde (2022). Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
20. Michael Böhm,Javed Butler,Gerasimos Filippatos,João Ferreira,Stuart Pocock,Amr Abdin,Felix Mahfoud,Martina Brueckmann,Nicholas Gollop,Tomoko Iwata,Piotr Ponikowski,Christoph Wanner,Faiez Zannad,Milton Packer,Stefan Anker (2022). Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
21. Yuliya Lytvyn,Petter Bjornstad,Jacob Udell,Julie Lovshin,David Cherney (2017). Sodium Glucose Cotransporter-2 Inhibition in Heart Failure.
22. Christian Sonesson,Peter Johansson,Eva Johnsson,Ingrid Gause-Nilsson (2016). Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
23. Rafael De La Espriella,Antoni Bayés-Genís,Herminio Morillas,Rafael Bravo,Verónica Vidal,Eduardo Núñez,Enrique Santas,Gema Miñana,Juan Sanchis,Lorenzo Fácila,Francisco Torres,Jose Górriz,Alfonso Valle,Julio Núñez (2020). Renal Function Dynamics Following Co-Administration of Sacubitril/Valsartan and Empagliflozin in Patients with Heart Failure and Type 2 Diabetes.
24. Jaromír Hradec (2018). Pharmacological therapy for chronic heart failure.
25. Enrico Fabris,Marco Merlo,Claudio Rapezzi,Roberto Ferrari,Marco Metra,Maria Frigerio,Gianfranco Sinagra (2019). Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach.
26. Vincenzo Nuzzi,Antonio Cannatà,Paolo Manca,Matteo Castrichini,Giulia Barbati,Aneta Aleksova,Enrico Fabris,Massimo Zecchin,Marco Merlo,Giuseppe Boriani,Gianfranco Sinagra (2020). Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry.
27. D Bhatt,M Szarek,P Steg,C Cannon,L Leiter,D Mcguire,J Lewis,M Riddle,A Voors,M Metra,L Lund,M Komajda,J Testani,C Wilcox,P Ponikowski,R Lopes,S Verma,P Lapuerta,B; Soloist-Whf Trial Pitt,Investigators (2020). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
28. Dominick Raphael,Abdu Mogella,Elias Mtalemwa,Beatrice Kabuka (2022). Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series.
29. Carolyn Lam,Chanchal Chandramouli,Vineeta Ahooja,Subodh Verma (2019). SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects.
30. Carlos Escobar,Luis Manzano (2019). Mineralocorticoid Receptor Antagonists and Acute Heart Failure.
31. Wilfried Mullens,Kevin Damman,Veli-Pekka Harjola,Alexandre Mebazaa,Hans-Peter Brunner-La Rocca,Pieter Martens,Jeffrey Testani,W Tang,Francesco Orso,Patrick Rossignol,Marco Metra,Gerasimos Filippatos,Petar Seferovic,Frank Ruschitzka,Andrew Coats (2019). The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of Cardiology.
32. Bishoy Abraham,Michael Megaly,Mina Sous,Mina Fransawyalkomos,Marwan Saad,Robert Fraser,Joel Topf,Steven Goldsmith,Mengistu Simegn,Bradley Bart,Zain Azzo,Nancy Mesiha,Rajaninder Sharma (2019). Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.
33. Josep Masip,W Frank Peacok,Mattia Arrigo,Xavier Rossello,Elke Platz,Louise Cullen,Alexandre Mebazaa,Susanna Price,Héctor Bueno,Salvatore Di Somma,Mucio Tavares,Martin Cowie,Alan Maisel,Christian Mueller,Òsar Miró (2022). Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology.
34. Farzad Rahimi,Mehrbod Vakhshoori,Maryam Heidarpour,Fatemeh Nouri,Kiyan Heshmat-Ghahdarijani,Mohammad Fakhrolmobasheri,Davood Shafie (2021). Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF).
35. Meredith Brisco‐bacik,Jozine Ter Maaten,Steven Houser,Natasha Vedage,Veena Rao,Tariq Ahmad,F Wilson,Jeffrey Testani (2018). Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
36. M Colvin-Adams,A Taylor (2007). Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure..
37. Karl Hammermeister,Diane Fairclough,Caroline Emsermann,Richard Hamman,Michael Ho,Stephanie Phibbs,Mary Plomondon,Robert Valuck,David West,John Steiner (2009). Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
38. Keith Ferdinand,Uri Elkayam,Donna Mancini,Elizabeth Ofili,Ileana Piña,Inder Anand,Arthur Feldman,Dennis Mcnamara,Christopher Leggett (2014). Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure Trial.
39. A Aleksova,M Merlo,M Zecchin,G Sabbadini,G Barbati,G Vitrella,A Di Lenarda,G Sinagra (2010). Impact of Atrial Fibrillation on Outcome of Patients with Idiopathic Dilated Cardiomyopathy: Data from the Heart Muscle Disease Registry of Trieste.
40. Gerhard Hindricks,Tatjana Potpara,Nikolaos Dagres,Elena Arbelo,Jeroen Bax,Carina Blomström-Lundqvist,Giuseppe Boriani,Manuel Castella,Gheorghe-Andrei Dan,Polychronis Dilaveris,Laurent Fauchier,Gerasimos Filippatos,Jonathan Kalman,Mark La Meir,Deirdre Lane,Jean-Pierre Lebeau,Maddalena Lettino,Gregory Lip,Fausto Pinto,G Thomas,Marco Valgimigli,Isabelle Van Gelder,Bart Van Putte,Caroline Watkins,Paulus Kirchhof,Michael Kühne,Victor Aboyans,Anders Ahlsson,Pawel Balsam,Johann Bauersachs,Stefano Benussi,Axel Brandes,Frieder Braunschweig,A Camm,Davide Capodanno,Barbara Casadei,David Conen,Harry Crijns,Victoria Delgado,Dobromir Dobrev,Heinz Drexel,Lars Eckardt,Donna Fitzsimons,Thierry Folliguet,Chris Gale,Bulent Gorenek,Karl Haeusler,Hein Heidbuchel,Bernard Iung,Hugo Katus,Dipak Kotecha,Ulf Landmesser,Christophe Leclercq,Basil Lewis,Julia Mascherbauer,Jose Merino,Béla Merkely,Lluís Mont,Christian Mueller,Klaudia Nagy,Jonas Oldgren,Nikola Pavlović,Roberto Pedretti,Steffen Petersen,Jonathan Piccini,Bogdan Popescu,Helmut Pürerfellner,Dimitrios Richter,Marco Roffi,Andrea Rubboli,Daniel Scherr,Renate Schnabel,Iain Simpson,Evgeny Shlyakhto,Moritz Sinner,Jan Steffel,Miguel Sousa-Uva,Piotr Suwalski,Martin Svetlosak,Rhian Touyz,Nikolaos Dagres,Elena Arbelo,Jeroen Bax,Carina Blomström-Lundqvist,Giuseppe Boriani,Manuel Castella,Gheorghe-Andrei Dan,Polychronis Dilaveris,Laurent Fauchier,Gerasimos Filippatos,Jonathan Kalman,Mark La Meir,Deirdre Lane,Jean-Pierre Lebeau,Maddalena Lettino,Gregory Lip,Fausto Pinto,G Neil Thomas,Marco Valgimigli,Isabelle Van Gelder,Caroline Watkins,Tahar Delassi,Hamayak Sisakian,Daniel Scherr,Alexandr Chasnoits,Michel Pauw,Elnur Smajić,Tchavdar Shalganov,Panayiotis Avraamides,Josef Kautzner,Christian Gerdes,Ahmad Alaziz,Priit Kampus,Pekka Raatikainen,Serge Boveda,Giorgi Papiashvili,Lars Eckardt,Vassilios Vassilikos,Zoltán Csanádi,David Arnar,Joseph Galvin,Alon Barsheshet,Pasquale Caldarola,Amina Rakisheva,Ibadete Bytyçi,Alina Kerimkulova,Oskars Kalejs,Mario Njeim,Aras Puodziukynas,Laurent Groben,Mark Sammut,Aurel Grosu,Aneta Boskovic,Abdelhamid Moustaghfir,Natasja Groot,Lidija Poposka,Ole-Gunnar Anfinsen,Przemyslaw Mitkowski,Diogo Cavaco,Calin Siliste,Evgeny Mikhaylov,Luca Bertelli,Dejan Kojic,Robert Hatala,Zlatko Fras,Fernando Arribas,Tord Juhlin,Christian Sticherling,Leila Abid,Ilyas Atar,Oleg Sychov,Matthew Bates,Nodir Zakirov (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
41. Stefan Hohnloser (2009). New Pharmacological Options for Patients With Atrial Fibrillation: The ATHENA Trial.
42. Paulus Kirchhof,A Camm,Andreas Goette,Axel Brandes,Lars Eckardt,Arif Elvan,Thomas Fetsch,Isabelle Van Gelder,Doreen Haase,Laurent Haegeli,Frank Hamann,Hein Heidbüchel,Gerhard Hindricks,Josef Kautzner,Karl-Heinz Kuck,Lluis Mont,G Ng,Jerzy Rekosz,Norbert Schoen,Ulrich Schotten,Anna Suling,Jens Taggeselle,Sakis Themistoclakis,Eik Vettorazzi,Panos Vardas,Karl Wegscheider,Stephan Willems,Harry Crijns,Günter Breithardt (2020). Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.
43. Line Melgaard,Thure Overvad,Martin Jensen,Thomas Christensen,Gregory Lip,Torben Larsen,Peter Nielsen (2021). Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis.
44. Scott Solomon,Pardeep Jhund,Brian Claggett,Pooja Dewan,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc Sabatine,Silvio Inzucchi,Akshay Desai,Olof Bengtsson,Daniel Lindholm,Mikaela Sjostrand,Anna Langkilde,John Mcmurray (2020). Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan.
45. Alberto Aimo,Konstantinos Pateras,Kimon Stamatelopoulos,Antoni Bayes-Genis,Carlo Lombardi,Claudio Passino,Michele Emdin,Georgios Georgiopoulos (2020). Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
46. Umut Karabulut,Kudret Keskin,Dilay Karabulut,Ece Yiğit,Zerrin Yiğit (2021). Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction.